Agile Therapeutics to report in fresh generation of transdermal contraceptives Dr.

Rossi is certainly scheduled to present at 9:30 am in Room C. Agile Therapeutics is privately kept and backed by high-quality health care investors, including ProQuest, a healthcare venture capital firm that is controlling over $875 million; the Hillman Firm and its own Affiliates, a diversified expense firm active in capital raising investing for over 25 years; TL Ventures, with over $1.4 billion under administration; and PA Early Stage Companions, with more than $235 million under management.. Agile Therapeutics to report in fresh generation of transdermal contraceptives Dr. Thomas M. Rossi, President and CEO of Agile Therapeutics, Inc., will report on the company’s progress in developing a new generation of transdermal contraceptives at the BIO 2007 annual international conference on biotechnology.The trial provides enrolled a total of 86 sufferers at 18 sites in the usa. Patients in the procedure group received intramuscular shots of TRCs in to the affected limb, while control individuals received intramuscular shots with an electrolyte remedy . Both groupings received appropriate regular of look after their condition also. While the primary objective of this trial is certainly to assess safety in sufferers with CLI, additional efficacy methods are also becoming monitored, including time to treatment failing , amputation price, wound size and severity.